Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Receivables (2016 - 2025)

Lexaria Bioscience's Change in Receivables history spans 11 years, with the latest figure at -$280314.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 357.14% year-over-year to -$280314.0; the TTM value through Nov 2025 reached -$175447.0, up 33.41%, while the annual FY2025 figure was $213881.0, 501.62% up from the prior year.
  • Change in Receivables for Q4 2025 was -$280314.0 at Lexaria Bioscience, down from $10229.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $408045.0 in Q4 2023 and bottomed at -$280314.0 in Q4 2025.
  • The 5-year median for Change in Receivables is -$4660.5 (2023), against an average of -$7704.4.
  • The largest annual shift saw Change in Receivables surged 1382.87% in 2021 before it plummeted 808.65% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $119111.0 in 2021, then fell by 29.03% to $84538.0 in 2022, then surged by 382.68% to $408045.0 in 2023, then plummeted by 73.28% to $109014.0 in 2024, then crashed by 357.14% to -$280314.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Change in Receivables are -$280314.0 (Q4 2025), $10229.0 (Q3 2025), and $26964.0 (Q2 2025).